© 2019 by Joshua Mansour, MD. Proudly created with Wix.com

Published Manuscripts

“Significant Anti-tumor Effect of Bevacizumab in Treatment of Pineal Gland Glioblastoma Multiforme”

Targeted Oncology. 2014 Dec;9(4):395-8. doi: 10.1007/s11523-014-0327-8. Epub 2014 Jul 8

“Tumor Lysis Syndrome in Retroperitoneal  Sarcoma”

Journal of Investigative Medicine High Impact Case Reports..  2014 Jul-Sep; 2(3): 2324709614542340. Published online 2014 Jul 4. doi:  10.1177/2324709614542340

“ Congestive Heart Failure during induction with Anthracycline based therapy in patients with Acute Promyelocytic Leukemia may be more frequent than expected”

J Community Support Oncol. 2014 Nov;12(11):390-3. doi: 10.12788/jcso.0084

"Prognostic Value of Day 30 Platelet Count After First Induction Cycle in Acute Myeloid Leukemia."

Journal of Community and Supportive Oncology. October 2015.

“Utility and impact of early t(15;17) identification by Fluorescence In-Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)”

Int J Lab Hematol. 2015 Aug; 37(4):515-20. doi: 10.1111/ijlh.12326. Epub 2015 Jan 14.

"Pneumatosis Intestinalis in an Acute Promyelocytic Leukemia (APL) patient”

Case Reports in Hematology. October 2015. 2015;2015:576042. doi: 10.1155/2015/576042. Epub 2015 Oct 8

“Prognostic value of complete remission with superior platelet counts in Acute Myeloid Leukemia"

Journal of Community and Supportive Oncology. 2016 Feb;14(2):66-71. doi: 10.12788/jcso.0231

“Recurrent Metastatic Parotid Carcinosarcoma in an Asymptomatic Patient”

Journal of Investigative Medicine High Impact Case Reports. 2016 Nov 4;4(4):2324709616676590

“Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management”

MOJ Clinical Med Case Rep. July 2017. DOI: 10.15406/mojcr.2017.07.00190

"Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction"

Journal of Community and Supportive Oncology.  August 2017. . doi: https://doi.org/10.12788/jcso.0340

“Outcomes of Patients with Multiple Myeloma Refractory to CD38 Targeted Monoclonal Antibody Therapy”

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7

Published Abstracts

“Serum Alkaline Phosphatase Level on Day 4 of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker for CD34 Mobilization and Collection.”

Abstract # 65543 Publication # 4519. Blood. November, 2013

“Utility of D-Dimer As a Marker for Diffrentiation Syndrome and Infections in Acute Promyelocytic Leukemia (APL)”

Abstract # 65814 Publication # 4986. Blood. November, 2013

‚Äč“Day 30 Platelet Count as a Prognostic Marker of Survival in Acute Myeloid Leukemia.”

Blood 124 (21). December, 2014

“Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction.”

J Clin Oncol 33. June, 2015 (suppl; abstr e14027)

“Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Treatment.”
“Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment.”
“Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies.”